Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 211: The major clinical use of Nimodipine is in which of the following conditions?

A. Hypertension
B. Angina pectoris
C. Subarachnoid hemorrhage (Correct Answer)
D. Raynaud's phenomenon

Explanation: **Explanation:** **Nimodipine** is a second-generation dihydropyridine (DHP) calcium channel blocker (CCB). While it shares the basic mechanism of other DHPs—blocking L-type calcium channels—it possesses unique pharmacological properties that dictate its clinical utility. **Why Subarachnoid Hemorrhage (SAH) is correct:** Nimodipine is highly **lipid-soluble**, allowing it to readily cross the blood-brain barrier. It has a high affinity for cerebral blood vessels. Following a subarachnoid hemorrhage, patients are at high risk for **delayed cerebral ischemia** caused by secondary vasospasm. Nimodipine is the drug of choice to prevent and treat this vasospasm, thereby improving neurological outcomes and reducing mortality. **Why other options are incorrect:** * **A & B (Hypertension & Angina):** While other DHPs like Amlodipine or Nifedipine are mainstays for hypertension and stable angina due to their potent peripheral vasodilatory effects, Nimodipine is relatively weak in these areas and is not used clinically for systemic blood pressure control. * **D (Raynaud’s phenomenon):** Nifedipine is the preferred CCB for Raynaud’s. Nimodipine’s cerebrovascular selectivity makes it unnecessary and less effective for peripheral vasospastic disorders. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** In SAH, Nimodipine is given **orally** (or via nasogastric tube). It should **never** be given intravenously as it can cause severe hypotension. * **Selectivity:** Remember the mnemonic: **N**imodipine for **N**euro (Cerebral vessels). * **Other CCB Specifics:** * **Nifedipine:** Used in preterm labor (Tocolytic). * **Verapamil:** DOC for Paroxysmal Supraventricular Tachycardia (PSVT). * **Clevidipine:** Shortest acting CCB, used in hypertensive emergencies.

Question 212: Which calcium channel blocker agent is used in the treatment of hypertension?

A. Prazosin
B. Lidoflazin
C. Captopril
D. Nifedipine (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Nifedipine** Nifedipine is a **Dihydropyridine (DHP)** calcium channel blocker (CCB). It works by inhibiting L-type calcium channels in the vascular smooth muscle, leading to peripheral vasodilation and a reduction in systemic vascular resistance. This mechanism makes it a first-line agent for the management of chronic hypertension and hypertensive emergencies (specifically the long-acting formulations). **Analysis of Incorrect Options:** * **A. Prazosin:** This is a selective **alpha-1 adrenergic blocker**. While it is used for hypertension, it is not a calcium channel blocker. It is frequently used in patients with comorbid Benign Prostatic Hyperplasia (BPH). * **B. Lidoflazin:** This is a calcium channel blocker, but it is historically classified as a **coronary vasodilator** used primarily for angina pectoris, not as a standard treatment for hypertension. It is rarely used in modern clinical practice. * **C. Captopril:** This is an **ACE Inhibitor** (Angiotensin-Converting Enzyme Inhibitor). It lowers blood pressure by preventing the conversion of Angiotensin I to Angiotensin II, a potent vasoconstrictor. **High-Yield NEET-PG Pearls:** * **Classification of CCBs:** Divided into DHPs (Nifedipine, Amlodipine—act on vessels) and Non-DHPs (Verapamil, Diltiazem—act on the heart). * **Side Effects:** A common side effect of Nifedipine is **ankle edema** (due to precapillary vasodilation) and reflex tachycardia. * **Clinical Note:** Short-acting sublingual nifedipine is now avoided in hypertensive emergencies due to the risk of precipitous hypotension and myocardial infarction; long-acting (extended-release) forms are preferred. * **Drug of Choice:** CCBs are preferred antihypertensives in elderly patients and those of African descent.

Question 213: In left ventricular failure (LVF), which of the following drugs can be administered?

A. Propranolol
B. Morphine (Correct Answer)
C. Amlodipine
D. Epinephrine

Explanation: **Explanation:** In Acute Left Ventricular Failure (LVF) leading to pulmonary edema, **Morphine** is a drug of choice due to its multi-modal therapeutic effects: 1. **Venodilation:** It increases venous capacitance (pooling of blood), which reduces **preload** and decreases pulmonary congestion. 2. **Anxiolysis:** It relieves the intense anxiety and "air hunger" associated with dyspnea, reducing sympathetic overactivity. 3. **Afterload Reduction:** At high doses, it causes mild arterial dilation, reducing the workload on the failing heart. **Analysis of Incorrect Options:** * **Propranolol:** A non-selective beta-blocker. It is **contraindicated** in acute LVF because it has negative inotropic effects, which can further depress cardiac output and worsen heart failure. * **Amlodipine:** A dihydropyridine calcium channel blocker. While it reduces afterload, it has no role in the acute management of LVF and may cause reflex tachycardia, increasing myocardial oxygen demand. * **Epinephrine:** A potent sympathomimetic. While it increases contractility, it significantly increases heart rate and myocardial oxygen consumption, which can worsen ischemia and trigger arrhythmias in a failing heart. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Acute Pulmonary Edema:** **LMNOP** (Loop diuretics/Furosemide, Morphine, Nitrates, Oxygen, Position/Posturing). * **Morphine Caution:** While beneficial, it must be used cautiously in patients with COPD or respiratory depression. * **Specific Antidote:** If morphine causes respiratory depression, **Naloxone** is the competitive antagonist used for reversal.

Question 214: Arjuna terminalia is used in the treatment of which condition?

A. Myocardial Infarction (MI)
B. Congestive Heart Failure (CHF) (Correct Answer)
C. Atrial Fibrillation (AF)
D. Rheumatic Heart Disease (RHD)

Explanation: **Explanation:** *Terminalia arjuna* (Arjuna) is a traditional Ayurvedic medicinal plant widely recognized in modern pharmacology for its **cardiotonic** and **inotropic** properties. **Why Congestive Heart Failure (CHF) is correct:** The bark of the Arjuna tree contains active glycosides (like arjunetin), flavonoids, and tannins. These compounds exert a positive inotropic effect, increasing the force of myocardial contraction without significantly increasing the heart rate. It also possesses antioxidant properties and improves coronary artery blood flow. In CHF, where the heart’s pumping ability is compromised, Arjuna helps improve the Left Ventricular Ejection Fraction (LVEF) and reduces cardiac workload, making it a valuable adjuvant therapy. **Why other options are incorrect:** * **Myocardial Infarction (MI):** While Arjuna has some cardioprotective and anti-ischemic properties, it is not the standard of care for acute MI, which requires immediate thrombolysis, antiplatelets, or PCI. * **Atrial Fibrillation (AF):** AF requires rate or rhythm control (e.g., Beta-blockers, Digoxin, or Amiodarone) and anticoagulation. Arjuna does not possess significant anti-arrhythmic properties for supraventricular tachycardias. * **Rheumatic Heart Disease (RHD):** RHD is an autoimmune sequela of streptococcal infection involving valvular damage. Arjuna cannot reverse structural valvular deformities. **NEET-PG High-Yield Pearls:** * **Active Ingredients:** Arjunolic acid, arjunetin, and arjunolone. * **Mechanism:** It acts similarly to digitalis (mild inotropic) but with a much wider therapeutic index and fewer side effects. * **Other uses:** It is also studied for its hypolipidemic (lowering LDL) and anti-atherogenic effects. * **Key Association:** In exams, always link *Terminalia arjuna* with **CHF** and **Cardioprotection**.

Question 215: A drug effect that is produced by therapeutic doses of both timolol and amiodarone is blockade of:

A. Cardiac Na+ channels
B. Cardiac K+ channels
C. Beta adrenoceptors (Correct Answer)
D. Alpha-adrenoceptors

Explanation: **Explanation:** The correct answer is **C. Beta adrenoceptors**. **Mechanism and Concept:** * **Timolol** is a potent, non-selective **Beta-blocker** (Class II antiarrhythmic). Its primary mechanism of action is the competitive antagonism of $\beta_1$ and $\beta_2$ adrenoceptors. * **Amiodarone** is a unique **Class III antiarrhythmic** drug with a broad spectrum of activity. While its primary effect is blocking cardiac $K^+$ channels (prolonging action potential duration), it also possesses significant **non-competitive beta-blocking activity** (Class II effect), as well as $Na^+$ channel (Class I) and $Ca^{2+}$ channel (Class IV) blocking properties. Therefore, both drugs share the common effect of beta-adrenoceptor blockade at therapeutic doses. **Analysis of Incorrect Options:** * **A. Cardiac $Na^+$ channels:** While Amiodarone has some $Na^+$ channel blocking activity (Class I effect), Timolol does not possess membrane-stabilizing activity (MSA) or $Na^+$ channel blocking properties at therapeutic doses. * **B. Cardiac $K^+$ channels:** This is the hallmark of Class III agents like Amiodarone. Timolol, a pure beta-blocker, does not block $K^+$ channels. * **D. Alpha-adrenoceptors:** Amiodarone has mild $\alpha$-blocking activity (contributing to vasodilation), but Timolol is a pure beta-antagonist and does not block alpha-receptors. **NEET-PG High-Yield Pearls:** * **Amiodarone** is the "broad-spectrum" antiarrhythmic because it exhibits actions of all four Vaughan-Williams classes. * **Timolol** is frequently used topically in glaucoma to decrease aqueous humor production but can cause systemic side effects (like bronchospasm or bradycardia) due to systemic absorption. * **Side effect profile of Amiodarone:** Remember the "6 Ps": **P**ulmonary fibrosis, **P**hotodermatitis (Blue-grey skin), **P**eripheral neuropathy, **P**rolonged QT, and **P**roblems with Thyroid (Hypo/Hyper) and Liver (**P**arenchyma).

Question 216: Which of the following drugs acts as a Rho kinase inhibitor?

A. Trimetazidine
B. Fasudil (Correct Answer)
C. Pinacidil
D. Ranolazine

Explanation: **Explanation:** **Fasudil** is the correct answer as it is a potent and selective **Rho-kinase (ROCK) inhibitor**. Rho-kinase is an enzyme that plays a critical role in vascular smooth muscle contraction by inhibiting myosin light chain phosphatase. By inhibiting ROCK, Fasudil promotes vasodilation and reduces vascular resistance. Clinically, it is primarily used in the management of **cerebral vasospasm** following subarachnoid hemorrhage and is being investigated for pulmonary hypertension. **Analysis of Incorrect Options:** * **A. Trimetazidine:** This is a **p-FOX inhibitor** (partial fatty acid oxidation inhibitor). It shifts myocardial metabolism from fatty acid oxidation to glucose oxidation, which requires less oxygen, thereby protecting cardiomyocytes during ischemia. * **C. Pinacidil:** This drug belongs to the class of **K+ATP channel openers**. By opening potassium channels, it causes hyperpolarization of smooth muscle cells, leading to peripheral vasodilation. It is used as an antihypertensive. * **D. Ranolazine:** This is a **late sodium channel blocker** ($I_{Na}$ inhibitor). It prevents calcium overload in ischemic cardiac myocytes, improving myocardial relaxation and reducing anginal pain without significantly affecting heart rate or blood pressure. **High-Yield Pearls for NEET-PG:** * **Fasudil** is unique because it targets the "calcium sensitization" pathway rather than direct calcium channel blockade. * **Trimetazidine and Ranolazine** are classified as "Metabolic Modulators" or "Add-on therapies" for chronic stable angina. * **Nicorandil** is a dual-action drug: it acts as both a K+ATP channel opener and a nitrate-like vasodilator.

Question 217: What is the drug of choice for hypertensive emergency?

A. Intravenous Clevidipine
B. Intravenous Nicardipine (Correct Answer)
C. Intravenous Diltiazem
D. Intravenous Verapamil

Explanation: **Explanation:** In a **hypertensive emergency** (defined as BP >180/120 mmHg with evidence of acute end-organ damage), the goal is a rapid but controlled reduction of blood pressure using parenteral agents with predictable pharmacokinetics. **Why Nicardipine is the Correct Answer:** Intravenous **Nicardipine**, a second-generation dihydropyridine calcium channel blocker (CCB), is currently considered a first-line drug of choice for most hypertensive emergencies. It is highly effective, has a rapid onset (5–15 minutes), and is easily titratable. Unlike other agents, it does not cause reflex tachycardia and has been shown to be safe in various scenarios, including neurological emergencies (stroke) and perioperative hypertension. **Analysis of Incorrect Options:** * **Clevidipine (Option A):** While also a dihydropyridine CCB used in emergencies, it is ultra-short-acting and formulated in a lipid emulsion. While effective, Nicardipine remains the more established and frequently cited "standard" in many clinical guidelines and exam patterns. * **Diltiazem and Verapamil (Options C & D):** These are non-dihydropyridine CCBs. They have significant **negative inotropic and chronotropic effects**, which can lead to heart failure or severe bradycardia. They are primarily used for rate control in arrhythmias (like AFib), not for the rapid reduction of blood pressure in emergencies. **High-Yield NEET-PG Pearls:** * **Labetalol** is the other major first-line agent, especially preferred in **Aortic Dissection** and **Preeclampsia/Eclampsia**. * **Sodium Nitroprusside**, once the gold standard, is now a second-line agent due to the risk of **cyanide/thiocyanate toxicity**. * **Fenoldopam** (D1 agonist) is the drug of choice in hypertensive emergencies with **renal impairment**. * **Esmolol** is the drug of choice for intraoperative hypertension.

Question 218: Which of the following is NOT true about nitroglycerin?

A. Causes AV conduction delay (Correct Answer)
B. Causes tolerance
C. Causes reflex tachycardia
D. Causes hypotension

Explanation: Nitroglycerin (NTG) is a potent vasodilator primarily used in the management of angina pectoris and heart failure. Its mechanism involves the release of nitric oxide (NO), which increases cGMP levels, leading to smooth muscle relaxation. **Explanation of the Correct Option:** * **Option A (Causes AV conduction delay):** This is the **incorrect** statement regarding NTG. Nitroglycerin acts predominantly on vascular smooth muscle (venous > arterial). It has **no direct effect** on the cardiac conduction system or the AV node. Drugs that cause AV conduction delay (negative dromotropes) include Beta-blockers, Calcium Channel Blockers (Verapamil/Diltiazem), and Digoxin. **Explanation of Incorrect Options:** * **Option B (Causes tolerance):** Continuous exposure to nitrates leads to "tachyphylaxis" or tolerance, likely due to the depletion of sulfhydryl groups or oxidative stress. This is managed by providing a "nitrate-free interval" (usually 8–12 hours at night). * **Option C (Causes reflex tachycardia):** Significant peripheral vasodilation leads to a drop in blood pressure, which triggers a compensatory baroreceptor reflex, resulting in an increased heart rate. * **Option D (Causes hypotension):** By increasing venous capacitance (venodilation) and decreasing systemic vascular resistance, NTG reduces preload and afterload, leading to a decrease in blood pressure. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Sublingual NTG is the DOC for acute anginal attacks. * **Monday Disease:** Industrial workers exposed to nitrates develop tolerance during the week but lose it over the weekend, leading to headaches and tachycardia upon re-exposure on Mondays. * **Contraindication:** Never co-administer with **Sildenafil** (PDE-5 inhibitors) as it can cause life-threatening hypotension. * **Storage:** NTG is volatile and light-sensitive; it should be stored in dark glass containers.

Question 219: A patient with acute myocardial infarction is being treated in the intensive care unit and develops left ventricular failure with a raised central venous pressure. Nitroglycerin is to be administered. Which route of administration would be most suitable?

A. Sublingual
B. Oral
C. Intravenous bolus injection
D. Slow intravenous infusion (Correct Answer)

Explanation: **Explanation:** The correct answer is **Slow intravenous infusion (Option D)**. In the setting of **Acute Myocardial Infarction (AMI)** complicated by **Left Ventricular Failure (LVF)** and pulmonary congestion (indicated by raised CVP), the primary goal of Nitroglycerin (NTG) is to reduce cardiac preload and afterload. **Why Slow IV Infusion is Correct:** * **Titratability:** In a critical care setting, hemodynamic stability is volatile. A slow IV infusion allows for precise, minute-to-minute titration of the dose based on blood pressure and clinical response. * **Rapid Onset & Short Half-life:** NTG has a very short half-life (~1–3 minutes). Continuous infusion ensures a steady-state plasma concentration, which can be instantly terminated if hypotension occurs. * **Hemodynamic Control:** It effectively reduces pulmonary capillary wedge pressure (PCWP) and relieves pulmonary edema without causing the drastic pressure swings associated with bolus doses. **Why Other Options are Incorrect:** * **Sublingual (A):** While excellent for acute angina pectoris, it provides a transient effect and lacks the sustained, controlled delivery required for managing LVF in an ICU setting. * **Oral (B):** NTG undergoes extensive **first-pass metabolism** (low bioavailability). Oral nitrates (like Isosorbide mononitrate) are used for chronic prophylaxis, not acute emergencies. * **Intravenous Bolus (C):** A bolus injection can cause sudden, severe hypotension and reflex tachycardia, which increases myocardial oxygen demand and can worsen the infarct. **Clinical Pearls for NEET-PG:** * **Mechanism:** NTG is a prodrug that releases **Nitric Oxide (NO)**, stimulating guanylyl cyclase to increase **cGMP**, leading to dephosphorylation of myosin light chains and vasodilation. * **Preference:** At low doses, NTG is a selective **venodilator** (reduces preload); at higher doses, it also acts as an **arteriodilator** (reduces afterload). * **Storage:** IV NTG must be administered using **non-PVC (glass or polyethylene) tubing** because the drug is adsorbed by plastic. * **Tachyphylaxis:** Continuous infusion for >24 hours can lead to **nitrate tolerance** due to the depletion of sulfhydryl groups.

Question 220: Which of the following drugs is NOT useful in compensated heart failure?

A. Na+/K+ ATPase inhibitors
B. Aldosterone antagonists
C. BNP analogue (Correct Answer)
D. Beta receptor antagonists

Explanation: The key to answering this question lies in distinguishing between drugs used for **chronic (compensated) heart failure** and those used for **acute decompensated heart failure (ADHF)**. ### **Explanation of the Correct Option** **C. BNP Analogue (e.g., Nesiritide):** Nesiritide is a recombinant form of Brain Natriuretic Peptide. While it causes vasodilation and natriuresis, it is administered via **intravenous infusion** and has a very short half-life. Therefore, it is strictly indicated for the management of **acute decompensated heart failure** to reduce pulmonary capillary wedge pressure. It has no role in the long-term management of compensated heart failure and has not shown mortality benefits in chronic settings. ### **Why Other Options are Incorrect** * **A. Na+/K+ ATPase inhibitors (e.g., Digoxin):** These are used in chronic heart failure to improve symptoms and reduce hospitalization rates, especially in patients with co-existing atrial fibrillation. * **B. Aldosterone antagonists (e.g., Spironolactone):** These are "disease-modifying" drugs. They prevent cardiac remodeling and fibrosis, significantly reducing mortality in patients with chronic heart failure (NYHA Class II-IV). * **D. Beta receptor antagonists (e.g., Carvedilol, Metoprolol, Bisoprolol):** Though once contraindicated, they are now a cornerstone of chronic heart failure therapy. They prevent sympathetic overactivation and reduce mortality. *Note: They should be avoided in acute/uncompensated phases.* ### **High-Yield Clinical Pearls for NEET-PG** * **Mortality-Reducing Drugs in HF:** ACE inhibitors/ARBs, Beta-blockers, Aldosterone antagonists, SGLT2 inhibitors, and ARNI (Sacubitril/Valsartan). * **Digoxin** reduces hospitalization but **does not** reduce mortality. * **Nesiritide Side Effect:** The most common side effect is dose-related hypotension; it may also impact renal function. * **Sacubitril** (in ARNI) works by inhibiting **Neprilysin**, the enzyme that breaks down endogenous BNP.

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free